ClinicalTrials.gg
CompletedNCT00332462Updated Mar 7, 2011Results posted

A Study to Evaluate the Efficiency of Intravenously Administered Cyclosporine in de Novo Liver Transplant Recipients

A Phase 4 interventional study of Cyclosporine (Sandimmun® i.v.) and Cyclosporine (Sandimmun® Optoral) in Liver Transplantation, sponsored by Novartis Pharmaceuticals. Completed at 1 site in Germany. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2011-03-07.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
34
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The aim of this exploratory study is to evaluate the rejection rate in patients treated with cyclosporine (CsA) preceding oral administration of cyclosporine micro emulsion in de novo liver recipients. The blood levels of CsA and CsA micro emulsion will be monitored by C-2h monitoring. In addition, this study will assess the safety of this treatment regimen.

02

Conditions studied

  • Liver Transplantation

Keywords

  • Liver transplantation, Cyclosporine
03

In context

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,721 studies on the registry; 222 are open to participants now.

Of its 586 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • About to undergo a primary liver transplant (including living donor, split liver).
  • Expected to be capable of study participation for full 6 months post-transplantation.
  • Allograft will be possible.

Exclusion criteria

Exclusion Criteria

  • The surgery is a multi-organ transplant.
  • The patient has previously been transplanted with any other organ.
  • The graft derives from a non-heart beating donor.

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    Cyclosporine (Sandimmun®)

    Period 1: Cyclosporine (Sandimmun® i.v.) intravenous given 2 times daily as an infusion over four hours staring at a dose of 2 X 200 mg/day for 7 days followed by Period 2: Sandimmun® Optoral microemulsion oral capsule twice daily starting at an initial daily dose of 8-12 mg/kg/day. Dosages were adjusted based on blood levels at two hours to achieve protocol specified target levels.

    Drug: Cyclosporine (Sandimmun® i.v.) · Drug: Cyclosporine (Sandimmun® Optoral)

Interventions

  • Cyclosporine (Sandimmun® i.v.) intravenous given 2 times daily as an infusion over four hours staring at a dose of 2 X 200 mg/day for 7 days. Dosages were adjusted based on blood levels at two hours to achieve protocol specified target levels.

    Also known as: Sandimmun

  • Sandimmun® Optoral microemulsion oral capsule twice daily starting at an initial daily dose of 8-12 mg/kg/day. Dosages were adjusted based on blood levels at two hours to achieve protocol specified target levels.

    Also known as: Sandimmun

06

What researchers measure

Primary outcomes

  1. Incidence of Biopsy Proven Acute Rejection During the First 3 Months Post de Novo Liver Transplantation

    Number of patients with biopsy proven acute rejection (BPAR) within 3 months after post de novo liver transplantation. In all suspected rejection episodes an allograft biopsy was performed within a 48 hour period of initiation of an anti-rejection therapy. A designated pathologist graded the biopsies according to the Banff criteria into mild, moderate or severe BPAR.

    Time frame: 3 months

Secondary outcomes

  1. Incidence, Safety and Tolerability of Cyclosporine Intravenous (i.v.) During 6 Months Post de Novo Liver Transplantation

    The secondary efficacy endpoints included: the incidence of BPAR at 6 months; the incidence of treated acute rejection (TAR) / steroid-resistant acute rejection at 3 and 6 months; the incidence of BPAR with moderate/severe histological grading at 3 and 6 months; time to the first BPAR, the first TAR / steroid-resistant acute rejection and BPAR with moderate/severe histological grading; patient death at 3 and 6 months; and graft loss at 3 and 6 months.

    Time frame: 3 or 6 months after transplantation

07

Results

Posted Jan 11, 2011

Participant flow

Participant flow — Overall Study
MilestoneCyclosporine (Sandimmun®)
Started34
Patients treated with sandimmun® i.v.34
Patients treated with sandimmun® optoral29
Completed18
Not completed16
Withdrew: Adverse event5
Withdrew: Abnormal lab value1
Withdrew: Unsatisfactory therapeutic effect4
Withdrew: No longer requires study drug1
Withdrew: Death3
Withdrew: Graft loss2

Outcome measures

PrimaryIncidence of Biopsy Proven Acute Rejection During the First 3 Months Post de Novo Liver Transplantation

Number of patients with biopsy proven acute rejection (BPAR) within 3 months after post de novo liver transplantation. In all suspected rejection episodes an allograft biopsy was performed within a 48 hour period of initiation of an anti-rejection therapy. A designated pathologist graded the biopsies according to the Banff criteria into mild, moderate or severe BPAR.

Time frame:
3 months
Reported as:
Number · Participants
Incidence of Biopsy Proven Acute Rejection During the First 3 Months Post de Novo Liver Transplantation
ParticipantsCyclosporine (Sandimmun®)
patients with BPAR within 3 months after Tx : YES8
patients with BPAR within 3 months after Tx : NO26
SecondaryIncidence, Safety and Tolerability of Cyclosporine Intravenous (i.v.) During 6 Months Post de Novo Liver Transplantation

The secondary efficacy endpoints included: the incidence of BPAR at 6 months; the incidence of treated acute rejection (TAR) / steroid-resistant acute rejection at 3 and 6 months; the incidence of BPAR with moderate/severe histological grading at 3 and 6 months; time to the first BPAR, the first TAR / steroid-resistant acute rejection and BPAR with moderate/severe histological grading; patient death at 3 and 6 months; and graft loss at 3 and 6 months.

Time frame:
3 or 6 months after transplantation
Reported as:
Number · Participants
Incidence, Safety and Tolerability of Cyclosporine Intravenous (i.v.) During 6 Months Post de Novo Liver Transplantation
Participants3 Months After Transplantation6 Months After Transplantation
Patients with BPAR : YESNA10
Patients with BPAR : NONA24
Patients with TAR : YES78
Patients with TAR : NO2726
Patients w/ steroid-resistant acute rejection:YES23
Patients w/ steroid-resistant acute rejection:NO3231
BPAR w/ moderate/severe histological grading:YES44
BPAR w/ moderate/severe histological grading:NO3030
Occurence of Death : YES33
Occurence of Death : NO3131
Occurence of Graft loss : YES33
Occurence of Graft loss : NO3131

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cyclosporine (Sandimmun® i.v.)—18/34 (52.9%)34/34 (100%)
Cyclosporine (Sandimmun® Optoral)—14/29 (48.3%)29/29 (100%)
Most frequent serious events
Showing 10 of 40
Most frequent serious events
EventCyclosporine (Sandimmun® i.v.)Cyclosporine (Sandimmun® Optoral)
HAEMORRHAGEVascular disorders5/340/29
CHOLANGITISHepatobiliary disorders0/343/29
RESPIRATORY FAILURERespiratory, thoracic and mediastinal disorders3/341/29
ASCITESGastrointestinal disorders0/342/29
BILIARY ISCHAEMIAHepatobiliary disorders0/342/29
INFECTIONInfections and infestations0/342/29
RENAL FAILURERenal and urinary disorders2/342/29
COMPLICATIONS OF TRANSPLANTED LIVERInjury, poisoning and procedural complications2/341/29
POST PROCEDURAL HAEMORRHAGEInjury, poisoning and procedural complications2/341/29
RENAL FAILURE ACUTERenal and urinary disorders2/340/29
Most frequent other events
Showing 10 of 79
Most frequent other events
EventCyclosporine (Sandimmun® i.v.)Cyclosporine (Sandimmun® Optoral)
CHOLESTASISHepatobiliary disorders20/3410/29
ANAEMIABlood and lymphatic system disorders18/3410/29
RENAL FAILURERenal and urinary disorders18/347/29
PROCEDURAL PAINInjury, poisoning and procedural complications17/342/29
HYPERGLYCAEMIAMetabolism and nutrition disorders17/342/29
HYPOTENSIONVascular disorders17/344/29
PLEURAL EFFUSIONRespiratory, thoracic and mediastinal disorders16/344/29
CONSTIPATIONGastrointestinal disorders15/347/29
HYPOALBUMINAEMIAMetabolism and nutrition disorders15/343/29
INSOMNIAPsychiatric disorders13/348/29

Baseline characteristics

Age Continuous
Age Continuous(years)Cyclosporine (Sandimmun®)
Mean53.2 ± 9.6
Sex: Female, Male
Sex: Female, Male(Participants)Cyclosporine (Sandimmun®)
Female12
Male22
08

Study locations

1 site
  • Novartis Investigational Site
    Various Cities, Germany
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2006, a primary completion of Apr 2008 and a completion of Jan 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2011, 2 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2006
First posted
Jun 1, 2006
Start
May 2006
Primary completionActual
Apr 2008
CompletionActual
Jan 2009
Results first posted
Jan 11, 2011
Last update
Mar 7, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 7, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00332462
First posted
Jun 1, 2006
Start date
May 2006
Primary completion
Apr 2008
Completion
Jan 2009
Results posted
Jan 11, 2011
Last update
Mar 7, 2011

Study contacts

Novartis
study director · Novartis
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cyclosporine

Start the discussion